Like most of us, I am glad this year is coming to a close and am looking forward to a better year ahead. My holiday wish to my fellow Chondrosarcoma Warriors and families is that you enjoy and cherish the holidays with your family and wish that you have no pain or suffering. It hurts [...]
We are $167 away from reaching our goal to hire a Marketing / Public Relations expert to help us with broadcast media and social media getting the word out about Chondrosarcoma Awareness Day. The event will take place on February 6 in honor of Shayna’s birthday. We aim to do the following: 1. Educate the [...]
> > Snyder Family Holiday Letter 2020 > > > Merry Christmas and Happy Holidays from the Snyder family in Albuquerque, New Mexico! Like you and yours, we’ve had a year at Casa Del Snyder where the only constants has been the constant turmoil, upheaval, uncertainty and change. We’ve managed to make it through [...]
Agios to Sell Cancer Portfolio to Servier for $1.8 Billion By Emma Court December 21, 2020, 7:00 AM EST Updated on December 21, 2020, 10:18 AM EST Agios Pharmaceuticals Inc. said it agreed to sell its portfolio of oncology drugs to Servier Pharmaceuticals LLC for $1.8 billion in a move that will increase the biotechnology [...]
On November 17, 2020 the Chondrosarcoma CS Foundation, Inc. held its first International Virtual Dialogue entitled: Straight Talk About Chondrosarcoma. There were 109 registrations and at one time we had over 80 participants attend the Virtual Dialogue consisting of CS Patients, Family members, Oncologists, Sarcoma Specialists, Radiation Oncologists, Pathologists, CS Clinical Researchers and others. “Straight [...]
Hello fellow warriors….well some good news for all of us: I spoke today via video with a doc whose advice I get every 3 months when my CT scans are done, Jonathan Trent MD, Ph.D. (how’s that for qualified??) He runs a clinical trial for CS which has been going for years and gives me [...]
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist Vivek Subbiah 1, Robert E Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock PMID: 22914439 PMCID: PMC3496030 DOI: 10.1158/1535-7163.MCT-12-0358 Free PMC article Abstract Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors [...]
New type of immunotherapy may pave the way for better cancer treatments by Karolinska Institutet From left: First author Silke Eisinger and last author Mikael Karlsson from Karolinska Institutet in Sweden. Credit: Mitch Eisinger Immunotherapy for cancer has made great advances and many patients can now receive effective treatments that were not available 10 years [...]
Karina Galoian, Ph.D., is a research associate professor in the Department of Orthopaedics at the University of Miami Leonard M. Miller School of Medicine. She also leads the departmental Institutional Review Board and is Research Director of the Sarcoma Disease Site Group at Sylvester Comprehensive Cancer Center. For the past 10 years, Dr. Galoian has [...]